Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

MAB1759 Anti-CD59 Antibody, clone 2/24

MAB1759
100 µg  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
HFC, IFMPurifiedMonoclonal Antibody
Description
Catalogue NumberMAB1759
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-CD59 Antibody, clone 2/24
OverviewBIOCHEMISTRY:

p I = 6.1
Alternate Names
  • Protectin
References
Product Information
FormatPurified
PresentationPurified immunoglobulin. The antibody is supplied in phosphate buffered saline, pH 7.4, containing 0.2% bovine serum albumin and 0.1% sodium azide. The characteristics of each lot are tested by electrophoresis and flow cytometry.
Quality LevelMQ100
Applications
ApplicationDetect CD59 using this Anti-CD59 Antibody, clone 2/24 validated for use in FC & IF.
Key Applications
  • Flow Cytometry
  • Immunofluorescence
Application NotesThis monoclonal is useful in studies of complement and homologous restriction of complement action of the properties of GPI linked proteins and in the characterisation of cells from patients with PNH.

SUGGESTED USAGE DILUTION

1. Flow cytometry and indirect immunofluorescence 1:25

Dilute with isotonic buffer. Use 50 μl of the appropriate dilution per 1x10E6 cells in 100 μl buffer.
Biological Information
ImmunogenHuman erythrocytes
Clone2/24
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostMouse
SpecificityThis antibody binds to a 17-25kD glycoprotein (Fletcher et al., 1990a,b) which is distributed on human cells and has a glycosyl-phosphatidylinositol (GPI) linkage to the plasma membrane(Hadam, 1989). It is identical to other CD59 monoclonals, MEM-43 and YTH 53.1, defined at the 4th International Conference on Human Leucocyte Differentiation Antigens(Davies et al., 1989; Stefanova et al., 1989). CD59 is an inhibitor of attack by autologous complement(Ojcius et al., 1990) possibly by limiting incorporation of C9 into the membrane complex(Rollins & Sims, 1990; Meri et al., 1990). GPI linked proteins such as CD59 are deficient on cells from patients with the acquired clonal disorder paroxysmal nocturnal haemoglobulinuria (PNH) in which the erythrocytes are susceptible to lysis by complement and leading to anemia(Rosse, 1990). Evidence suggests that CD59 may be the most important complement regulatory protein missing in PNH(Fletcher et al., 1990; Yamashina et al., 1990).

Cell reactivity (Fletcher et al., 1990a,b; Hadam, 1989):

The antibody reacts with all leucocytes, platelets, fibroblasts, erythrocytes and most cell lines. It is negative on U937 and Daudi cell lines. It is reduced on affected cells from patients with PNH with a distribution reflecting the clonal nature of the disease.
IsotypeIgG1
Species Reactivity
  • Human
Antibody TypeMonoclonal Antibody
Entrez Gene Number
Gene Symbol
  • CD59
  • MACIF
  • MIN2
  • MIN3
  • PROTECTIN
  • HRF-20
  • 16.3A5
  • MSK21
  • EJ16
  • HRF20
  • EL32
  • G344
  • MIC11
  • MIN1
  • Protectin
  • MAC-IP
  • MGC2354
  • EJ30
  • MIRL
  • p18-20
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P13987 # Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.
SIZE: 128 amino acids; 14177 Da
SUBUNIT: Interacts with T-cell surface antigen CD2.
SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor, GPI-anchor.
PTM: N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. & Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.
SIMILARITY: SwissProt: P13987 ## Contains 1 UPAR/Ly6 domain.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStore at 2 to 8°C, for up to 6 months. For prolonged periods, store below -20°C in undiluted aliquots. AVOID REPEATED FREEZE/THAW CYCLES.

WARNING: The monoclonal reagent solution contains 0.1% sodium azide as a preservative. Due to potential hazards arising from the build up of this material in pipes, spent reagent should be disposed of with liberal volumes of water.
Packaging Information
Material Size100 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
MAB1759 04053252502262

Documentation

Anti-CD59 Antibody, clone 2/24 SDS

Title

Safety Data Sheet (SDS) 

Anti-CD59 Antibody, clone 2/24 Certificates of Analysis

TitleLot Number
Mouse monoclonal antibody: CD59, purified - 3190893 3190893
Mouse monoclonal antibody: CD59, purified - ME9HN8712 ME9HN8712

References

Reference overviewPub Med ID
G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies.
Nakamura, K; Salomonis, N; Tomoda, K; Yamanaka, S; Conklin, BR
PloS one  4  e7780  2009

Show Abstract Full Text Article
19936228 19936228